Heavy Chain-Only Antibody FR4 Substitution for Lower Aggregation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for producing heavy chain-only antibodies (HCAbs) suffer from a high propensity for aggregation and solubility issues, limiting their effectiveness and stability.
Innovation Solution
Replace the native amino acid residue at the first position of the fourth framework region (FR4) in the HCAb with a different amino acid residue, such as a polar or positively charged residue like arginine, to disrupt surface-exposed hydrophobic patches, thereby reducing aggregation and enhancing stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If heavy chain-only antibodies are produced using conventional methods, then they can bind to target antigens, but they exhibit high aggregation propensity and solubility issues
Solution Approach 1:
The patent applies parameter changes by modifying the amino acid sequence at specific positions in the framework regions (FR1, FR2, FR3, FR4) of the heavy chain-only antibody. By changing residues at these positions, the patent alters the physical-chemical properties of the antibody to reduce hydrophobicity and aggregation while preserving antigen binding affinity.
Solution Approach 2:
The patent applies local quality by making specific modifications at defined locations within the antibody structure (framework regions FR1-FR4) rather than changing the entire molecule. This localized approach allows targeted optimization of specific areas responsible for aggregation while maintaining the overall folding and antigen-binding functionality of the HCAb.
2Stability of the object's composition
If the amino acid residue at the first position of FR4 is replaced to disrupt hydrophobic patches, then aggregation is reduced, but the antibody structure must be precisely controlled
Solution Approach 1:
The patent applies preliminary action by pre-defining the optimal amino acid sequences at the framework region positions before antibody production. The specific residue substitutions (e.g., W to R at FR4 position 101) are predetermined based on computational modeling and structural analysis, allowing for controlled and reproducible modification during the antibody generation process.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified HCAbs exhibit reduced aggregation propensity and maintain high binding affinity to target antigens, with dissociation constants ranging from 1 pM to 1 μM, suitable for applications in therapeutic and diagnostic contexts.
Implementation Method 1
Replace the native amino acid residue at the first position of the fourth framework region (FR4) in the HCAb with a different amino acid residue, such as a polar or positively charged residue like arginine, to disrupt surface-exposed hydrophobic patches
Data Source
AI summary
Human or chimeric heavy chain-only antibodies are provided, in the native amino acid residue at the first position of the fourth framework region (FR4) of said HCAb is substituted by a different amino acid residue that is capable of disrupting a surface-exposed hydrophobic patch comprising or associated with the native amino acid residue at that position.